ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Liu, Si-Yang Maggie; Tu, Hai-Yan; Wei, Xue-Wu; Yan, Hong-Hong; Dong, Xiao-Rong; Cui, Jiu-Wei; Zhou, Zhen; Xu, Chong-Rui; Zheng, Ming-Ying; Li, Yang-Si; Wang, Zhen; Bai, Xiao-Yan; Li, An-Na; Sun, Yue-Li; Huang, Jie; Lin, Jia-Xin; Ke, E. E.; Xu, Bing-Fei; Lu, Chang; Du, Yingying; Chen, Yuan; Ma, Rui; Wang, Bu-Hai; Cang, Shun-Dong; Wang, Bin-Chao; Chen, Hua-Jun; Yang, Jin-Ji; Li, Yangqiu*; Zhou, Qing*; Wu, Yi-Long*广东省人民医院; 安徽医科大学; 华中科技大学; 吉林大学; 南方医科大学; 上海交通大学; 1
Nature Medicine2023-8DOI: 10.1038/s41591-023-02461-x
5被引12阅读
引用收藏
分享

摘要

To explore targeted treatment options in patients with non-small-cell lung cancer (NSCLC) with rare genetic mutations in the context of a patient-centric clinical trial, we initiated, in parallel, a phase 2 adaptive umbrella trial consisting of a criteria-fulfilled (CF) cohort and a compassionate use (CU) cohort under expanded eligibility criteria, and a prospective real-world study (RWS). Here, we present efficacy and safety data from 48 patients with treatment-naive, advanced HER2-mutant NSCLC treated with the pan-HER receptor tyrosine kinase inhibitor pyrotinib (CF and CU cohorts) or physician's therapy of choice (RWS cohort). In the phase 2 trial CF cohort (n = 28), the primary endpoint was reached with an objective response rate of 35.7% after pyrotinib treatment. Secondary endpoints included disease control rate (89.3%), median progression-free survival (PFS) (7.3 months), median overall survival (OS) (14.3 months) and toxicity, which was acceptable, with grade 3 or 4 treatment-related adverse events occurring in three patients (10.7%). The phase 2 trial CU cohort (n = 12) showed an objective response rate of 16.7%, disease control rate of 83.4%, median PFS of 4.7 months and median OS of 14.2 months after pyrotinib treatment. The RWS cohort (n = 8) had no responses to physician's therapy of choice, while median PFS and OS were 3.0 and 12.2 months, respectively. @@@ Treatment of patients with HER2-mutant non-small-cell lung cancer with the pan-HER inhibitor pyrotinib in a phase 2 trial or compassionate use showed a favorable objective response rate, whereas patients treated in parallel by physician's choice in a real-world study did not.

学科与关键词

关键词
OPEN-LABELMULTICENTERHER2
相关
加载中…
  • Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study
    Li, Yiqun; Tong, Zhongsheng; Wu, Xinhong; Ouyang, Quchang; Cai, Li; Li, Wei; Yu, Zhiyong; Han, Zhengxiang; Wang, Xiaojia; Li, Man; Wang, Haibo; Li, Li; Yang, Jin; Niu, Zhaofeng; Wang, Qitang; Xu, Binghe*International Journal of Cancer, 2023, 153(10): 1809-1818.
  • Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy
    Tu, Hai-Yan; Yin, Kai; Zhao, Xiaotian; Ke, E-E; Wu, Si-Pei; Li, Yang-Si; Zheng, Mei-Mei; Liu, Si-Yang Maggie; Xu, Chong-Rui; Sun, Yue-Li; Lin, Jia-Xin; Bai, Xiao-Yan; Zhang, Yi-Chen; Zhou, Qing; Yang, Jin-Ji; Zhong, Wen-Zhao; Wang, Bing-Chao; Zhang, Xu-Chao; Zhu, Dongqin; Yang, Lingling; Ou, Qiuxiang; Wu, Yi-Long*Molecular Oncology, 2023, 17(8): 1581-1594.被引 1
  • Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial
    Zheng, Yabing; Cao, Wen-Ming; Shao, Xiying; Shi, Yanxia; Cai, Li; Chen, Wenyan; Liu, Jian; Shen, Peng; Chen, Yiding; Wang, Xian; Li, Huiping; Li, Man; Chen, Zhanhong*; Wang, Xiaojia*Nature Communications, 2023, 14(1): 8314.
查看全部 →

发表信息

论文状态
公开发表
期刊
Nature Medicine
发表日期
2023-08
卷期
第 29 卷, 第 8 期
页码
2079-+
DOI
10.1038/s41591-023-02461-x
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82072562]; Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]; Guangdong Provincial People's Hospital Scientific Research Funds for Leading Medical Talents in Guangdong Province [KJ012019426]; High-Level Hospital Construction Project [DFJH201810]

作者

  • L

    Liu, Si-Yang Maggie (第一作者)

    1

  • T

    Tu, Hai-Yan

    guangdong prov peoples hosp · southern med univ

查看全部 30 位作者收起作者
  • W

    Wei, Xue-Wu

    guangdong prov peoples hosp · southern med univ

  • Y

    Yan, Hong-Hong

    guangdong prov peoples hosp · southern med univ

  • D

    Dong, Xiao-Rong

    huazhong univ sci & technol

  • C

    Cui, Jiu-Wei

    1 · jilin univ

  • Z

    Zhou, Zhen

    shanghai jiao tong univ

  • X

    Xu, Chong-Rui

    guangdong prov peoples hosp · southern med univ

  • Z

    Zheng, Ming-Ying

    guangdong prov peoples hosp · southern med univ

  • L

    Li, Yang-Si

    guangdong prov peoples hosp · southern med univ

  • W

    Wang, Zhen

    guangdong prov peoples hosp · southern med univ

  • B

    Bai, Xiao-Yan

    guangdong prov peoples hosp · southern med univ

  • L

    Li, An-Na

    guangdong prov peoples hosp · southern med univ

  • S

    Sun, Yue-Li

    guangdong prov peoples hosp · southern med univ

  • H

    Huang, Jie

    guangdong prov peoples hosp · southern med univ

  • L

    Lin, Jia-Xin

    guangdong prov peoples hosp · southern med univ

  • K

    Ke, E. E.

    guangdong prov peoples hosp · southern med univ

  • X

    Xu, Bing-Fei

    guangdong prov peoples hosp · southern med univ

  • L

    Lu, Chang

    guangdong prov peoples hosp · southern med univ

  • D

    Du, Yingying

    1 · anhui med univ

  • C

    Chen, Yuan

  • M

    Ma, Rui

    liaoning canc hosp

  • W

    Wang, Bu-Hai

  • C

    Cang, Shun-Dong

    henan prov peoples hosp

  • W

    Wang, Bin-Chao

    guangdong prov peoples hosp · southern med univ

  • C

    Chen, Hua-Jun

    guangdong prov peoples hosp · southern med univ

  • Y

    Yang, Jin-Ji

    guangdong prov peoples hosp · southern med univ

  • L

    Li, Yangqiu (通讯)

    1

  • Z

    Zhou, Qing (通讯)

    guangdong prov peoples hosp · southern med univ

  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417